Tuesday 23 January 2018

Pre-tax profit of €573m for UCB

Gordon Deegan

Shannon-based pharmaceutical firm UCB Manufacturing Ireland recorded pre-tax profits of €573.7m in 2011.

Accounts filed with the Companies Office show that the chief factor behind the company returning to profit was an exceptional gain of €651m after a debt of that amount due to parent company, Belgian-based UCB, was waived.

The figures show that the Irish unit – formerly Schwarz Pharma – increased its turnover by 11pc to €90.2m in the 12 months to the end of December 2011.

In 2011, the numbers employed by the firm were reduced from 126 to 118, with the company's staff costs increasing from €9.6m to €9.8m.

The profit in that year follows a pre-tax loss of €71.9m in 2010.

The profit in 2011 also takes account of non-cash depreciation and amortisation costs totalling €21m.

According to the directors' report, "turnover continued to grow in 2011 with an overall increase of 11pc to over €90m due mainly to continued growth of Neupro in new and existing markets."

Neurpo is used to treat Parkinson's disease and Restless Leg Syndrome.

Irish Independent

Promoted Links

Business Newsletter

Read the leading stories from the world of Business.

Promoted Links

Also in Business